Recently released Phase 3 trial data show that adding tislelizumab to chemotherapy regimens as a first line treatment improved PFS in patients with squamous NSCLC, according to a press release.

Study patients were treatment-naïve adults with advanced squamous NSCLC. In total, 360 patients were randomized 1:1:1 to receive 200mg of tislelizumab with either paclitaxel and carboplatin or nab-paclitaxel and carboplatin, or chemotherapy alone. 

Study results showed that tislelizumab with either of the two chemotherapy regimens was statistically superior to chemotherapy alone at improving PFS.

The manufacturer said that they will discuss regulatory submissions and present this Phase 3 data at “an upcoming medical meeting.” Additionally, they noted that safety data were in line with previous safety risks associated with each of the study treatments—with no new safety concerns identified. 

Tislelizumab is currently approved to treat classical Hodgkin’s lymphoma in China. The drug is not approved for any use outside of China.

By MD /alert Staff